Submitted by NCIIA Guest on Thu, 09/27/2012 - 21:25
In August of 2009, Stanford University student Ben Cline and D-Rev CEO Krista Donaldson came to the first Sustainable Vision Advanced Invention to Venture (AI2V) workshop in Cambridge. Three years later, their product, Brilliance, a low cost, low maintenance opto-medical device to treat neonatal jaundice, is on the market in India and they are looking to expand to East Africa. Donaldson estimates that early data suggests 13 babies will get treatment per device per month in urban hospitals, which means lives saved and brain damage averted. These results will be closely tracked. Cline’s contribution has been instrumental in early stages of product development of Brilliance. His accomplishments, during later stages, in an advisory role to bring Brilliance to Point-of-Scale are also commendable. His early partnership with D-Rev, was a key factor to this success.
Note: This article has been corrected since its original post to address some factual errors.